日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

AKT 抑制剂 MK-2206 联合激素疗法治疗绝经后雌激素受体阳性转移性乳腺癌患者的 I 期研究

期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-15-2160
Cynthia X Ma, Cesar Sanchez, Feng Gao, Robert Crowder, Michael Naughton, Timothy Pluard, Allison Creekmore, Zhanfang Guo, Jeremy Hoog, A Craig Lockhart, Austin Doyle, Charles Erlichman, Matthew J Ellis
信号转导
肿瘤
乳腺癌
PI3K/Akt
发表日期：2016
文献求助 收藏

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

BKM120（Buparlisib）联合氟维司群治疗雌激素受体阳性转移性乳腺癌绝经后女性的 I 期临床试验

期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-15-1745
Cynthia X Ma, Jingqin Luo, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Malachi Griffith, Obi L Griffith, Zachary L Skidmore, Nicholas C Spies, Avinash Ramu, Lee Trani, Timothy Pluard, Gayathri Nagaraj, Shana Thomas, Zhanfang Guo, Jeremy Hoog, Jing Han, Elaine Mardis, Craig Lockhart, Matthew J E
肿瘤
乳腺癌
发表日期：2016
文献求助 收藏

CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer

CXCR4 蛋白表位模拟拮抗剂 POL5551 可破坏三阴性乳腺癌的转移并增强化疗效果

期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-15-0252
Jingyu Xiang, Michelle A Hurchla, Francesca Fontana, Xinming Su, Sarah R Amend, Alison K Esser, Garry J Douglas, Chidananda Mudalagiriyappa, Kathryn E Luker, Timothy Pluard, Foluso O Ademuyiwa, Barbara Romagnoli, Gérald Tuffin, Eric Chevalier, Gary D Luker, Michael Bauer, Johann Zimmermann, Rebecca
肿瘤
乳腺癌
发表日期：2015
文献求助 收藏